WO2017054786A1 - A production method of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin- 4-yl)urea and its deuterated analogs - Google Patents
A production method of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin- 4-yl)urea and its deuterated analogs Download PDFInfo
- Publication number
- WO2017054786A1 WO2017054786A1 PCT/CZ2016/000104 CZ2016000104W WO2017054786A1 WO 2017054786 A1 WO2017054786 A1 WO 2017054786A1 CZ 2016000104 W CZ2016000104 W CZ 2016000104W WO 2017054786 A1 WO2017054786 A1 WO 2017054786A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- accordance
- fluorobenzyl
- pimavanserin
- Prior art date
Links
- RKEWSXXUOLRFBX-UHFFFAOYSA-N CC(C)COc1ccc(CNC(N(Cc(cc2)ccc2F)C2CCN(C)CC2)=O)cc1 Chemical compound CC(C)COc1ccc(CNC(N(Cc(cc2)ccc2F)C2CCN(C)CC2)=O)cc1 RKEWSXXUOLRFBX-UHFFFAOYSA-N 0.000 description 1
- PLYWEOOWONUOBN-UHFFFAOYSA-N CN(CC1)CCC1NCc(cc1)ccc1F Chemical compound CN(CC1)CCC1NCc(cc1)ccc1F PLYWEOOWONUOBN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
Definitions
- the invention relates to an improved production method of l-(4-fluorobenzyl)-3-(4- isobutoxybenzyl)-l-(l— methylpiperidin-4-yl)urea of formula I, known under the generic name of pimavanserin.
- Pimavanserin is an inverse agonist of the serotonin 5-HT 2A receptor and is currently in the tartrate form in stage III of clinical trial for the treatment of psychosis in patients suffering from Parkinson's disease and has potential to become part of the therapy of other psychotic conditions.
- Pimavanserin of formula I is produced, according to the published patent applications (WO2004064738, WO2006036874, WO2006037043), from the input N-(4-fluorobenzyl)-l- methylpiperidine-4 ⁇ amine of formula II through a reaction with 1-isobutoxybenzyl isocyanate of formula III, providing crude pimavanserin (Diagram 1).
- the above mentioned methods of pimavanserin synthesis feature a number of disadvantages.
- the main disadvantages comprise the use of 4-isobutoxybenzyl isocyanate of formula III, which is, as all the substances of this type, toxic, unpleasantly malodorous and highly reactive.
- Another disadvantage is that the described methods of its synthesis either use the highly toxic phosgene, or the also toxic diphenyl phosphoryl azide (DPPA), which is additionally as all azides potentially explosive.
- DPPA diphenyl phosphoryl azide
- Partly deuterated analogs of pimavanserin are also described that exhibit, based on the kinetic isotope effect, lower sensitivity to metabolic degradation and can thus have the corresponding therapeutic advantages as a lower dosage, higher effect, lower inter-individual deviations and more (WO2008141057).
- their synthesis is analogous to the above mentioned methods described in the published patent applications WO2004064738, WO2006036874 and WO2006037043 with the use of partly deuterated input substances. Disclosure of the Invention
- the invention relates to a new efficient preparation method of highly pure l-(4-fluorobenzyl)-
- the invention relates to a new efficient preparation method of highly pure l-(4-fluorobenzyl)- 3-(4-isobutoxybenzyl)-l-(l-methylpiperidin-4-yl)urea - pimavanserin of formula I, which does not contain the amine of formula II, or the doubled impurity of formula IX.
- the method is based on the known 4-isobutoxybenzylamine of formula VII, which reacts with the reagent of formula X, preferably with ⁇ , -carbonyldiimidazole (CDI) of formula Xa, producing the correspondingly substituted N-(4-isobutoxybenzyl)-l -carbamide of formula XI.
- This reaction can be carried out in a number of solvents at an elevated temperature.
- Polar aprotic solvents of the ester or ether type are suitable, preferably tetrahydrofuran or 2-methyltetrahydrofuran.
- the reaction can be carried out at temperatures in the range from 40°C to the boiling point, preferably at 50 - 60°C.
- the heterocycle of formula XII falls off as a side product, which can be, together with the excess reagent of formula X, removed by washing with water, possibly with an addition of an inorganic base, preferably sodium carbonate, or an acid, preferably diluted hydrochloric acid.
- the obtained crude product can be repurified by crystallization from various solvents, preferably C2 - C4 alcohols with a straight or branched chain, preferably from isopropyl alcohol.
- the carbamide of formula XI obtained this way reacts with N-(4-fluorobenzyl)-l- methylpiperidine-4-amine of formula II in the second stage, producing l-(4-fluorobenzyl)-3- (4-isobutoxybenzyl)-l-(l-methylpiperidin-4-yl)urea - pimavanserin of formula I.
- the reaction can be carried out at temperatures in the range from 40°C to the boiling point, preferably at 50 - 60°C.
- the heterocycle of formula XII falls off as a side product, which can be removed by washing with water, possibly with an addition of an inorganic base, preferably sodium carbonate, or an acid, preferably diluted hydrochloric acid.
- the product can be obtained as a free base or as a salt with organic acids.
- the above mentioned reaction stages can be carried out either in two separate steps with isolation of the intermediate product of formula XI, or in a single step without isolation and purification.
- the mixture was further stirred at 60°C for 16 h, then the reaction mixture was washed with a 5% solution of sodium carbonate (2 x 100 ml) and water (1 x 100 ml). The organic phase was then evaporated on a vacuum evaporator, the amount of 9.33 g of the crude evaporation product was obtained. The evaporation product was recrystallized from isopropyl alcohol (50 ml), the amount of 8.5 g (67%) was obtained.
- N-(4-isobutoxybenzyl)-l H-imidazole- 1 -carbamide (XIa) 2.0 g; 7.32 mmol
- THF 25 ml
- N-(4-fluorobenzyl)-l-methylpiperidine-4-amine (II) 1.8 g; 8.05 mmol
- the mixture was diluted with MTBE (50 ml) and washed with a 5% solution of sodium hydrogen carbonate (1 x 50 ml) and water (2 x 50 ml).
- the organic phase was dried with magnesium sulfate and after removal of the drying agent by filtration evaporated until dry.
- the obtained evaporation product (3.3 g) was recrystallized from isopropyl alcohol (10 ml). The amount of 2.2 g of crystals (70%) was obtained.
- N-(4-fluorobenzyl)-l-methylpiperidine-4-amine (II) (8.2 g; 36.8 mmol) was added to the solution by dripping during 5 minutes and the mixture was further stirred for 2 h at 60°C.
- the reaction mixture was washed with 3.5% hydrochloric acid (1 x 70 ml, 1 x 20 ml) and subsequently with water (1 x 20 ml).
- the reaction mixture was subsequently washed with 3.5% hydrochloric acid (1 x 50 ml, 1 x 25 ml) and then with saturated salt brine (1 x 50 ml).
- the organic fraction was transferred to a flask and p- toluenesulfonic acid monohydrate (4.4 g; 23.2 mmol) in 2-methyltetrahydrofuran (25 ml) was added.
- the obtained turbid solution was evaporated until dry and the evaporation product (16.4 g) was dissolved in ethanol (120 ml).
- the hot ethanolic solution was filtered and after cooling and seeding the product crystallizes in the form of a salt.
- the amount of 9.5 g of the crystalline product was obtained (68%).
- the reaction mixture was washed with 3.5% hydrochloric acid (2 x 10 ml) and subsequently with water (1 x 10 ml).
- the organic fraction was evaporated until dry, the evaporation product was dissolved in isopropyl alcohol (10 ml) and a solution of p-toluenesulfonic hydrate (1.06 g; 5.58 mmol) in isopropyl alcohol (55 ml) was added to the solution obtained this way in a hot state.
- the mixture was slowly left to crystallize to the lab. , the separated crystalline fraction was removed by filtration and washed with ethyl methyl ketone. The amount of 2.31 g of the crystalline product was obtained (69%).
- the reaction mixture was washed with 3.5% hydrochloric acid (2 x 10 ml) and subsequently with water (1 x 10 ml).
- the organic fraction was evaporated until dry, the evaporation product was dissolved in isopropyl alcohol (10 ml) and a solution of p-toluenesulfonic hydrate (1.06 g; 5.58 mmol) in isopropyl alcohol (55 ml) was added to the solution obtained this way in a hot state.
- the mixture was slowly left to crystallize to the lab. t, the separated crystalline fraction was removed by filtration and washed with ethyl methyl ketone. The amount of 2.17 g of the crystalline product was obtained (65%).
Abstract
The present invention relates to an improved production method of 1-(4-fluorobenzyl)-3-(4--isobutoxybenzyl)-1-(1--methylpiperidin-4-yl)urea (Pimavanserin), an inverse agonist of the serotonin 5-HT2A receptor of formula (I). Crude pimavanserin prepared by this method contains a very low quantity of the disubstituted impurity.
Description
A production method of l-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-l-(l-methylpiperidin- 4-yl)urea and its deuterated analogs
Field of the invention
The invention relates to an improved production method of l-(4-fluorobenzyl)-3-(4- isobutoxybenzyl)-l-(l— methylpiperidin-4-yl)urea of formula I, known under the generic name of pimavanserin.
Pimavanserin is an inverse agonist of the serotonin 5-HT2A receptor and is currently in the tartrate form in stage III of clinical trial for the treatment of psychosis in patients suffering from Parkinson's disease and has potential to become part of the therapy of other psychotic conditions.
Background Art
Pimavanserin of formula I is produced, according to the published patent applications (WO2004064738, WO2006036874, WO2006037043), from the input N-(4-fluorobenzyl)-l- methylpiperidine-4~amine of formula II through a reaction with 1-isobutoxybenzyl isocyanate of formula III, providing crude pimavanserin (Diagram 1).
Diagram 1
The above mentioned patents also describe synthesis of N-(4-fluorobenzyl)-l- methylpiperidine-4-amine of formula II by reductive alkylation of 4-fluorobenzylamine of
formula IV with l-methylpiperidin-4-one of formula V. According to the above mentioned patents, the other component for synthesis of pimavanserin of formula I, 4-isobutoxybenzyl isocyanate of formula III can be obtained through a reaction of 4-isobutoxybenzylamine of formula VII, which can be prepared in two stages from 4-isobutoxybenzaldehyde of formula VI with phosgene or its equivalents. Another described synthesis of 4-isobutoxybenzyl isocyanate of formula III is based on 2-(4-isobutoxyphenyl)acetic acid of formula VIII, which provides, through a reaction with diphenyl phosphoryl azide (DPPA; diphenyl phosphorazidate), the isocyanate of formula III (Diagram 2).
Diagram 2
However, the above mentioned methods of pimavanserin synthesis feature a number of disadvantages. The main disadvantages comprise the use of 4-isobutoxybenzyl isocyanate of formula III, which is, as all the substances of this type, toxic, unpleasantly malodorous and highly reactive. Another disadvantage is that the described methods of its synthesis either use the highly toxic phosgene, or the also toxic diphenyl phosphoryl azide (DPPA), which is additionally as all azides potentially explosive.
Another disadvantage of the said method is the fact that crude pimavanserin of formula I contains some impurities the removal of which leads to considerable losses. Namely, as unpleasant impurities from this point of view N-(4-fluorobenzyl)-l-methylpiperidine-4-amine of formula II and l,3-bis(4-isobutoxybenzyl)urea of formula IX are mentioned.
Partly deuterated analogs of pimavanserin are also described that exhibit, based on the kinetic isotope effect, lower sensitivity to metabolic degradation and can thus have the corresponding therapeutic advantages as a lower dosage, higher effect, lower inter-individual deviations and more (WO2008141057). However, their synthesis is analogous to the above mentioned methods described in the published patent applications WO2004064738, WO2006036874 and WO2006037043 with the use of partly deuterated input substances. Disclosure of the Invention
The invention relates to a new efficient preparation method of highly pure l-(4-fluorobenzyl)-
3- (4-isobutoxybenzyl)-l-(l-methylpiperidin-4-yl)urea - pimavanserin that is based on the known intermediates of its synthesis, namely N-(4-fluorobenzyl)-l-methylpiperidine-4-amine of formula II and 4-isobutoxybenzylamine of formula VII. The method is based on
4- isobutoxybenzylamine of formula VII, which is, in the first stage through a reaction with the reagent of formula X (where X = CH, N; R = H, alkyl C1-C3), converted to the correspondingly substituted N-(4-isobutoxybenzyl)-l -carbamide of formula XI. In the next stage, it is converted, through a reaction with N-(4-fluorobenzyl)-l-methylpiperidine-4-amine of formula II, to crude pimavanserin of formula I, which contains a very low quantity of the disubstituted impurity of formula IX (Diagram 3).
Diagram 3
Detailed description of the Invention
The invention relates to a new efficient preparation method of highly pure l-(4-fluorobenzyl)- 3-(4-isobutoxybenzyl)-l-(l-methylpiperidin-4-yl)urea - pimavanserin of formula I, which does not contain the amine of formula II, or the doubled impurity of formula IX.
The method is based on the known 4-isobutoxybenzylamine of formula VII, which reacts with the reagent of formula X, preferably with Ι, -carbonyldiimidazole (CDI) of formula Xa, producing the correspondingly substituted N-(4-isobutoxybenzyl)-l -carbamide of formula XI. This reaction can be carried out in a number of solvents at an elevated temperature. Polar aprotic solvents of the ester or ether type are suitable, preferably tetrahydrofuran or 2-methyltetrahydrofuran. The reaction can be carried out at temperatures in the range from 40°C to the boiling point, preferably at 50 - 60°C. During the reaction the heterocycle of formula XII falls off as a side product, which can be, together with the excess reagent of formula X, removed by washing with water, possibly with an addition of an inorganic base, preferably sodium carbonate, or an acid, preferably diluted hydrochloric acid. The obtained crude product can be repurified by crystallization from various solvents, preferably C2 - C4 alcohols with a straight or branched chain, preferably from isopropyl alcohol.
The carbamide of formula XI obtained this way reacts with N-(4-fluorobenzyl)-l- methylpiperidine-4-amine of formula II in the second stage, producing l-(4-fluorobenzyl)-3- (4-isobutoxybenzyl)-l-(l-methylpiperidin-4-yl)urea - pimavanserin of formula I. The reaction can be carried out at temperatures in the range from 40°C to the boiling point, preferably at 50 - 60°C. During the reaction the heterocycle of formula XII falls off as a side product, which can be removed by washing with water, possibly with an addition of an inorganic base, preferably sodium carbonate, or an acid, preferably diluted hydrochloric acid. The product can be obtained as a free base or as a salt with organic acids.
The above mentioned reaction stages can be carried out either in two separate steps with isolation of the intermediate product of formula XI, or in a single step without isolation and purification.
The above described method of synthesis of pimavanserin of formula I is also applicable to the preparation of the respective partly deuterated analogs.
Examples
Example 1
N-(4-isobutoxybenzyl)- 1 H-imidazole- 1 -carbamide of formula XIa
To solid 4-isobutoxybenzylamine hydrochloride (10.0 g; 46.4 mmol) a solution of sodium carbonate (7.4 g; 69.5 mmol) in water (200 ml) was added, the mixture was then extracted with 2-methyltetrahydrofuran (2 x 100 ml) and the united extracts were dried with magnesium sulfate. After the removal of the drying agent by filtration the solution was heated up to 60°C in an oil bath and subsequently carbonyldiimidazole (11.3 g; 69.5 mmol) was added all at a time. The mixture was further stirred at 60°C for 16 h, then the reaction mixture was washed with a 5% solution of sodium carbonate (2 x 100 ml) and water (1 x 100 ml). The organic phase was then evaporated on a vacuum evaporator, the amount of 9.33 g of the crude evaporation product was obtained. The evaporation product was recrystallized from isopropyl alcohol (50 ml), the amount of 8.5 g (67%) was obtained. 1H NMR (CDC13, 500 MHz, 298 K): 8.08 (s, 1H, imidazole CH), 7.37 (t, 1H, J= 1.5 Hz, s, 1H, imidazole CH), 7.24 (d, 2H, J= 8.7 Hz, ArH), 7.05 - 7.00 (m, 1H5 NH), 6.96 - 6.95 (m, 1H, imidazole CH), 6.86 (d, 2H, J = 8.7 Hz, ArH), 4.50 (d, 2Η, J = 5.6 Hz, CH -NH), 3.70 (d, 2H, J = 6.6 Hz, CH2-CH-(CH3)2), 2.07 (nonet, 1H, J= 6.6 Hz, CH2-CH-(CH3)2), 1.02 (d, 6H, J = 6.7 Hz, CH2-CH-(CH3)2). 13C NMR (CDC13, 500 MHz, 298 ): 159.07 (Ar-C-0-CH2), 148.83 (NH-CO-N), 135.80 (imidazole CH), 130.48 (imidazole CH), 129.36 (ArCH), 128.73 (quart. ArQ, 116.13 (imidazole CH), 114.80 (ArCH), 74.47 (CH2-CH-(CH3)2), 44.46 (CH2-NH), 28.20 (CH2-CH- (CH3)2), 19.21 (CH2-CH-(CH3)2) Example 2
l-(4-Fluorobenzyl)-3-(4-isobutoxybenzyl)-l-(l-methylpiperidin-4-yl)urea of formula I
To a solution of N-(4-isobutoxybenzyl)-l H-imidazole- 1 -carbamide (XIa) (2.0 g; 7.32 mmol) in THF (25 ml) N-(4-fluorobenzyl)-l-methylpiperidine-4-amine (II) (1.8 g; 8.05 mmol) was added all at a time and the reaction flask was put in a bath heated up to 60°C. The mixture
was further stirred at 60°C for 4 h, then it was left to cool down to the lab. t. The mixture was diluted with MTBE (50 ml) and washed with a 5% solution of sodium hydrogen carbonate (1 x 50 ml) and water (2 x 50 ml). The organic phase was dried with magnesium sulfate and after removal of the drying agent by filtration evaporated until dry. The obtained evaporation product (3.3 g) was recrystallized from isopropyl alcohol (10 ml). The amount of 2.2 g of crystals (70%) was obtained.
Example 3
1 -(4-Fluorobenzyl)-3-(4-isobutoxybenzyl)- 1 -( 1 -methylpiperidin-4-yl)urea of formula I To a suspension of carbonyldiimidazole (Xa) (6.0 g; 36.8 mmol) in 2-methyltetrahydrofuran (60 ml) 4-isobutoxybenzylamine (VII) (6.0 g; 33.5 mmol) was added by dripping under an inert atmosphere at 60°C during 5 minutes, the mixture was further stirred for 1 h at 60°C. Then, N-(4-fluorobenzyl)-l-methylpiperidine-4-amine (II) (8.2 g; 36.8 mmol) was added to the solution by dripping during 5 minutes and the mixture was further stirred for 2 h at 60°C. The reaction mixture was washed with 3.5% hydrochloric acid (1 x 70 ml, 1 x 20 ml) and subsequently with water (1 x 20 ml). The organic fraction was evaporated until dry, the evaporation product was dissolved in ethyl methyl ketone (50 ml) and a solution of p- toluenesulfonic monohydrate (6.4 g; 33.5 mmol) in ethyl methyl ketone (25 ml) was added to the solution obtained this way in a hot state. The mixture was slowly left to cool to the lab. t, the separated crystalline fraction was removed by filtration and washed with ethyl methyl ketone. The amount of 15.1 g of the crystalline product was obtained (75%).
Example 4
1- (4-Fluorobenzyl)-3-(4-isobutoxybenzyl)-l-(l-methylpiperidin-4-yl)urea of formula I To a suspension of 4-isobutoxybenzylamine hydrochloride (VII) (5.0 g; 23.2 mmol) in
2- methyltetrahydrofuran (50 ml) carbonyldiimidazole (Xa) (4.1 g; 25.5 mmol) was added all at a time under an inert atmosphere at 60°C. Triethylamine (2.6 g; 25.5 mmol) was added by dripping to the suspension obtained this way during 10 minutes and the mixture was further stirred for 40 minutes at 60°C. Then, N-(4-fluorobenzyl)-l-methylpiperidine-4-amine (II) (5.7 g; 25.5 mmol) was added to the solution by dripping during 5 minutes and the mixture was further stirred for 4 h at 60°C and for 16 h at the lab. t. (overnight). The reaction mixture was subsequently washed with 3.5% hydrochloric acid (1 x 50 ml, 1 x 25 ml) and then with saturated salt brine (1 x 50 ml). The organic fraction was transferred to a flask and p- toluenesulfonic acid monohydrate (4.4 g; 23.2 mmol) in 2-methyltetrahydrofuran (25 ml) was
added. The obtained turbid solution was evaporated until dry and the evaporation product (16.4 g) was dissolved in ethanol (120 ml). The hot ethanolic solution was filtered and after cooling and seeding the product crystallizes in the form of a salt. The amount of 9.5 g of the crystalline product was obtained (68%).
Example 5
l-(4-Fluorobenzyl)-3-(4-isobutoxybenzyl)-l-(l-methylpiperidin-4-yl)urea of formula I
To a suspension o carbonylbis(2-methylimidazole) (1.17 g; 6.14 mmol) in 2- methyltetrahydrofuran (10 ml) 4-isobutoxybenzylamine (VII) (1.0 g; 5.58 mmol) was added by dripping under an inert atmosphere at 60°C during 2 minutes, the mixture was further stirred for 2 h at 60°C. Then, N-(4-fluorobenzyl)-l-methylpiperidine-4-amine (II) (1.36 g; 6.14 mmol) was added to the solution by dripping during 2 minutes and the mixture was further stirred for 4 h at 60°C. The reaction mixture was washed with 3.5% hydrochloric acid (2 x 10 ml) and subsequently with water (1 x 10 ml). The organic fraction was evaporated until dry, the evaporation product was dissolved in isopropyl alcohol (10 ml) and a solution of p-toluenesulfonic hydrate (1.06 g; 5.58 mmol) in isopropyl alcohol (55 ml) was added to the solution obtained this way in a hot state. The mixture was slowly left to crystallize to the lab. , the separated crystalline fraction was removed by filtration and washed with ethyl methyl ketone. The amount of 2.31 g of the crystalline product was obtained (69%).
Example 6
1 -(4-Fluorobenzyl)-3-(4-isobutoxybenzyl)- 1 -( 1 -methylpiperidin-4-yl)urea of formula I
To a suspension of l, -carbonyldi(l,2,4-triazole) (1.17 g; 6.14 mmol) in 2- methyltetrahydrofuran (10 ml) 4-isobutoxybenzylamine (VII) (1.0 g; 5.58 mmol) was added by dripping under an inert atmosphere at 60°C during 2 minutes, the mixture was further stirred for 2 h at 60°C. Then, N-(4-fluorobenzyl)-l-methylpiperidine-4-amine (II) (1.36 g; 6.14 mmol) was added to the solution by dripping during 2 minutes and the mixture was further stirred for 5 h at 60°C. The reaction mixture was washed with 3.5% hydrochloric acid (2 x 10 ml) and subsequently with water (1 x 10 ml). The organic fraction was evaporated until dry, the evaporation product was dissolved in isopropyl alcohol (10 ml) and a solution of p-toluenesulfonic hydrate (1.06 g; 5.58 mmol) in isopropyl alcohol (55 ml) was added to the solution obtained this way in a hot state. The mixture was slowly left to crystallize to the lab. t, the separated crystalline fraction was removed by filtration and washed with ethyl methyl ketone. The amount of 2.17 g of the crystalline product was obtained (65%).
Claims
1. A method for preparing pimavanserin of formula I,
wherein X is independently CH or N, and where R is hydrogen or a C1-C3 alkyl, producing the carbamide of formula XI,
2. The method of preparing in accordance with claim 1, characterized in that the reaction in step a) is carried out in polar aprotic solvents, preferably in tetrahydrofuran or 2-methyltetrahydrofuran.
3. The method of preparing in accordance with claims 1 and 2, characterized in that the input substance VII from step a) is added dropwise to the compound of formula X, which is present in a 5 to 20% excess, preferably in 10% excess, producing the compound of formula XI.
4. The method of preparing in accordance with claim 3, characterized in that the mixture obtained in step b) is further reacted with N-(4-fluorobenzyl)-l-methylpiperidine-4- amine of formula II, which is in 5 to 20% excess, preferably in 10% excess and without preceding isolation of the substance of formula XI.
5. The method of preparing in accordance with claim 1, characterized in that the compound of formula X is 1,1 '-carbonyldiimidazole (CDI) of formula Xa.
7. The compound of formula XI,
9. The method of preparing in accordance with claim 1, characterized in that in step b) the compound of formula XI is reacted with N-(4-fluorobenzyl)-l-methylpiperidine-4- amine of formula II, which is in 5 to 20% excess, preferably in 10% excess.
10. Deuterated analogs of pimavanserin of formula I prepared with the method in accordance with claims 1 to 6.
11. The compounds of formula I, obtained with the method in accordance with claims 1 to 10, containing at least 95% of the compound I and not containing the dimeric impurity of formula IX.
12. A method for purification pimavanserin of formula I, characterized in that pimavanserin is converted to a salt with organic acids, preferably with pivalic, oxalic,
succinic, maleic, fumaric, tartaric, citric, ?-toluenesulfonic, benzenesulfonic acid, more preferably with £>-toluenesulfonic acid, and the resulting salt is subsequently crystallized from suitable solvents comprising alcohols, esters of aliphatic acids, amides, ethers, or mixtures of these solvents, preferably from methanol, ethanol, 1- propanol, 2-propanol, 1-butanol, 2-methoxyethanol, methyl acetate, ethyl acetate, isopropyl acetate, N,N-dimethyl formamide, N,N-dimethyl acetamide, 1- methylpyrrolidone, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, l-methoxy-2-(2- methoxyethoxy)ethane.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZPV2015-688 | 2015-10-02 | ||
CZ2015-688A CZ2015688A3 (en) | 2015-10-02 | 2015-10-02 | A method of producing 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl) of urea and its deuterated analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017054786A1 true WO2017054786A1 (en) | 2017-04-06 |
Family
ID=57120970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CZ2016/000104 WO2017054786A1 (en) | 2015-10-02 | 2016-09-14 | A production method of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin- 4-yl)urea and its deuterated analogs |
Country Status (2)
Country | Link |
---|---|
CZ (1) | CZ2015688A3 (en) |
WO (1) | WO2017054786A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107216271A (en) * | 2017-06-02 | 2017-09-29 | 沈阳药科大学 | Tartaric acid Mo Fanselin impurity and preparation method thereof |
WO2018007842A1 (en) * | 2016-07-08 | 2018-01-11 | Egis Gyógyszergyár Zrt. | Pimavanserin salts useful for the production of a pharmaceutical preparation |
WO2019008595A1 (en) * | 2017-07-03 | 2019-01-10 | Jubilant Generics Limited (Formerly A Division Of Jubilant Life Sciences Limited) | Process for the preparation of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1- methylpiperidin-4-yl)urea and salts thereof |
CN110054583A (en) * | 2018-01-19 | 2019-07-26 | 广东东阳光药业有限公司 | A method of preparing piperazine Ma Selin or its salt |
WO2019179920A1 (en) | 2018-03-19 | 2019-09-26 | Lundbeck Pharmaceuticals Italy S.P.A. | Process for the manufacturing of pimavanserin |
IT201800009690A1 (en) | 2018-10-23 | 2020-04-23 | Lundbeck Pharmaceuticals Italy Spa | PROCESS FOR THE PRODUCTION OF PIMAVANSERINA |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004064738A2 (en) | 2003-01-16 | 2004-08-05 | Acadia Pharmaceuticals Inc. | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
WO2006037043A1 (en) | 2004-09-27 | 2006-04-06 | Acadia Pharmaceuticals Inc. | Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
WO2008141057A1 (en) | 2007-05-08 | 2008-11-20 | Auspex Pharmaceuticals, Inc. | Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea |
WO2014085362A1 (en) * | 2012-11-27 | 2014-06-05 | Acadia Pharmaceuticals Inc. | Methods for the treatment of parkinson's disease psychosis using pimavanserin |
CN104844502A (en) * | 2015-06-05 | 2015-08-19 | 济南涛瑞医药科技有限公司 | Preparation method of Pimavanserin |
CN105111135A (en) * | 2015-09-09 | 2015-12-02 | 安徽省逸欣铭医药科技有限公司 | Preparation method of substituted urea derivative |
CN105153016A (en) * | 2015-10-12 | 2015-12-16 | 北京诺康达医药科技有限公司 | Preparation method of pimavanserin |
CN105820110A (en) * | 2016-05-09 | 2016-08-03 | 杭州科巢生物科技有限公司 | Novel synthesis method for pimavanserin |
WO2016141003A1 (en) * | 2015-03-02 | 2016-09-09 | Teva Pharmaceutical Industries Ltd. | Processes and intermediates for the preparation of pimavanserin |
-
2015
- 2015-10-02 CZ CZ2015-688A patent/CZ2015688A3/en unknown
-
2016
- 2016-09-14 WO PCT/CZ2016/000104 patent/WO2017054786A1/en active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004064738A2 (en) | 2003-01-16 | 2004-08-05 | Acadia Pharmaceuticals Inc. | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
WO2006037043A1 (en) | 2004-09-27 | 2006-04-06 | Acadia Pharmaceuticals Inc. | Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
WO2006036874A1 (en) | 2004-09-27 | 2006-04-06 | Acadia Pharmaceuticals Inc. | Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation |
WO2008141057A1 (en) | 2007-05-08 | 2008-11-20 | Auspex Pharmaceuticals, Inc. | Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea |
WO2014085362A1 (en) * | 2012-11-27 | 2014-06-05 | Acadia Pharmaceuticals Inc. | Methods for the treatment of parkinson's disease psychosis using pimavanserin |
WO2016141003A1 (en) * | 2015-03-02 | 2016-09-09 | Teva Pharmaceutical Industries Ltd. | Processes and intermediates for the preparation of pimavanserin |
CN104844502A (en) * | 2015-06-05 | 2015-08-19 | 济南涛瑞医药科技有限公司 | Preparation method of Pimavanserin |
CN105111135A (en) * | 2015-09-09 | 2015-12-02 | 安徽省逸欣铭医药科技有限公司 | Preparation method of substituted urea derivative |
CN105153016A (en) * | 2015-10-12 | 2015-12-16 | 北京诺康达医药科技有限公司 | Preparation method of pimavanserin |
CN105820110A (en) * | 2016-05-09 | 2016-08-03 | 杭州科巢生物科技有限公司 | Novel synthesis method for pimavanserin |
Non-Patent Citations (1)
Title |
---|
PETAR A. DUSPARA ET AL: "Synthesis and Reactivity of N -Alkyl Carbamoylimidazoles: Development of N -Methyl Carbamoylimidazole as a Methyl Isocyanate Equivalent", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 77, no. 22, 16 November 2012 (2012-11-16), US, pages 10362 - 10368, XP055269988, ISSN: 0022-3263, DOI: 10.1021/jo302084a * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018007842A1 (en) * | 2016-07-08 | 2018-01-11 | Egis Gyógyszergyár Zrt. | Pimavanserin salts useful for the production of a pharmaceutical preparation |
CN107216271A (en) * | 2017-06-02 | 2017-09-29 | 沈阳药科大学 | Tartaric acid Mo Fanselin impurity and preparation method thereof |
CN107216271B (en) * | 2017-06-02 | 2018-11-13 | 沈阳药科大学 | Tartaric acid Mo Fanselin impurity and preparation method thereof |
WO2019008595A1 (en) * | 2017-07-03 | 2019-01-10 | Jubilant Generics Limited (Formerly A Division Of Jubilant Life Sciences Limited) | Process for the preparation of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1- methylpiperidin-4-yl)urea and salts thereof |
CN110054583A (en) * | 2018-01-19 | 2019-07-26 | 广东东阳光药业有限公司 | A method of preparing piperazine Ma Selin or its salt |
WO2019179920A1 (en) | 2018-03-19 | 2019-09-26 | Lundbeck Pharmaceuticals Italy S.P.A. | Process for the manufacturing of pimavanserin |
IT201800009690A1 (en) | 2018-10-23 | 2020-04-23 | Lundbeck Pharmaceuticals Italy Spa | PROCESS FOR THE PRODUCTION OF PIMAVANSERINA |
WO2020083825A1 (en) | 2018-10-23 | 2020-04-30 | Lundbeck Pharmaceuticals Italy S.P.A. | Process for the manufacturing of pimavanserin |
Also Published As
Publication number | Publication date |
---|---|
CZ2015688A3 (en) | 2017-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017054786A1 (en) | A production method of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin- 4-yl)urea and its deuterated analogs | |
KR101593253B1 (en) | Phenyl and benzodioxinyl substituted indazoles derivatives | |
JP6013326B2 (en) | Process for the preparation of chiral triazolones | |
JP3560986B2 (en) | 5-HT2C receptor agonist and aminoalkylindazole derivative | |
CA2861150C (en) | Morphinan derivative | |
JP2022023891A (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
UA128114C2 (en) | Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2hpyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use | |
JP2014521726A5 (en) | ||
TW201725207A (en) | Crystalline form of BTK kinase inhibitor and a preparation method thereof | |
HUE023239T4 (en) | Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto | |
WO2012168364A1 (en) | Apixaban preparation process | |
JP2013532164A (en) | Methods for preparing thrombin specific inhibitors | |
KR102266680B1 (en) | Polymorphic Forms of Belinostet and Methods of Making It | |
US20090264438A1 (en) | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha | |
SK21596A3 (en) | Application of substituted aryloxyalkyl diamines, these substances single, producing method thereof, pharmaceutical compositions on their base and their producing method | |
JPWO2010107115A1 (en) | Glycine transporter inhibitor | |
BR112020018562A2 (en) | PREPARATIVE PROCESS | |
AU781837B2 (en) | 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity | |
JP2002521334A (en) | Substituted benzimidazole antivirals | |
JP2019509308A (en) | Novel crystal form of 1- (5- (2,4-difluorophenyl) -1-((3-fluorophenyl) sulfonyl) -4-methoxy-1H-pyrrol-3-yl) -N-methylmethanamine salt | |
CZ216996A3 (en) | Indole derivatives, process of their preparation, their use and pharmaceutical compositions containing thereof | |
RU2536688C2 (en) | Novel benzamide derivatives | |
EA036954B1 (en) | Xanthine-substituted alkynyl carbamates/reverse carbamates as a2b antagonists | |
KR20100046026A (en) | Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds | |
RU2011153981A (en) | CRYSTAL FORMS 6- (1H-IMIDAZOL-1-IL) -2-Phenylquinazoline and its salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16778669 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16778669 Country of ref document: EP Kind code of ref document: A1 |